Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Strong Q4 with mid single digit sales and double digit core Oplnc
growth
Group 1
Q4
Change vs. PY2
FY
Change vs. PY
USD million
2021
2021
% USD
% cc
% USD
% cc
Net sales
13,229
4
6
51,626
6
4
Core operating income
3,819
9
12
16,588
8
10
6
Operating income
2,562
-3
-1
11,689
15
13
Net income
16,306
nm
nm
24,018
198
195
Ex. Roche divestment gain³
1,734
-17
-14
9,446
17
15
Core EPS (USD)
1.40
4
7
6.29
9
7
EPS (USD)
7.29
nm
nm
10.71
202
200
Ex. Roche divestment gain³
0.78
-15
-13
4.21
19
17
Free cash flow
3,027
-9
13,282
14
nm - Not meaningful 1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Financial Report. All % growth relate to cc unless
otherwise stated. 2. Q4 sales growth for Group includes +1% point impact from a reclassification of contract manufacturing from other revenue to sales. 3. See slide 54 for the reconciliation of IFRS results vs. results ex. Roche divestment gain
41 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation